Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Debiopharm Kicks Off Phase 1 Study of MRSA Antibiotic

By Drug Discovery Trends Editor | June 19, 2014

Debiopharm Group , a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).
 
This is a Phase 1, double-blind, placebo-controlled dose-escalation study that will evaluate the safety, tolerability, and pharmacokinetics of single oral doses of Debio 1450 in healthy subjects. This study complements the IV single-ascending dose Phase 1 trial recently presented at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2014) in Barcelona.
 
Debio 1450 is a prodrug of Debio 1452, a potent and selective FabI-inhibitor. FabI is a critical enzyme required for bacterial fatty acid biosynthesis. Debio 1452 has been successfully administered in a series of Phase 1 studies and a Phase 2 study where it demonstrated high efficacy in the treatment of acute bacterial skin and skin-structure infections (ABSSSI). Due to its unique selectivity for staphylococcal species, Debio 1450 is expected to preserve the human microbiota and thereby reduce antibiotic-associated side effects such as antibiotic-induced diarrhea or C. difficile overgrowth. Additionally, development of multiple drug resistant organisms like VRE (vancomycin resistant enterococci) is unlikely given the lack of activity on other bacterial species. Debio 1450 is efficiently and rapidly converted to the active metabolite Debio 1452 after both IV and oral administration in animals. Being able to treat staphylococcal infections with a safe treatment that allows for an IV/oral switch will bring much greater flexibility to physicians and patients and will be a major advance in addressing difficult to-treat infections.
 
“This study is another step towards the development of an IV/oral anti-infective agent for difficult-to-treat infections”, said Jean-Maurice Dumont, vice-president Medical Affairs, Debiopharm International. “Development of targeted antibiotics that preserve the indigenous microbiota will become an essential tool for the infectious disease doctor. The promising results obtained with Debio 1452 and Debio 1450 make us extremely confident on the high potential of these new drugs.”
 
Thierry Mauvernay, delegate of the Board of Debiopharm Group, added that “The fast launch of this Phase 1 study with Debio 1450, only a few months after its acquisition, shows our strong commitment to the rapid development of innovative anti-infectives. This drug represents not only a novel agent but a whole new class of antibiotics – a development driven by our current line of thinking about highly targeted antibiotics. In parallel, we are actively working on the development of new, rapid and powerful diagnostic tools that will allow safe and accurate use of our drugs. Debiopharm is determined to pursue developments in this challenging field and to become a major player in this therapeutic area.”
 
Date: June 19, 2014
Source: Debiopharm Group

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50